Other Events ·
Artiva halts AlloNK development and cuts workforce by 94% while exploring strategic alternatives
ARTVArtiva Biotherapeutics, Inc.
Artiva Biotherapeutics announced the discontinuation of its lead candidate AlloNK (AB-101) following updated clinical data showing insufficient durability of response and two Grade 5 safety events, including one likely linked to fludarabine toxicity. The company is reducing its workforce by approximately 94% to preserve capital while it explores strategic alternatives such as a merger, asset sale, or liquidation. Preliminary cash, cash equivalents, and investments stood at $319.1 million as of September 30, 2026. Artiva Biotherapeutics is a clinical-stage biotechnology company developing allogeneic natural killer cell therapies for autoimmune diseases.